Trial Profile
A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Erenumab for Treatment of Idiosyncratic Facial Pain Mimicking Rhinosinusitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Facial pain
- Focus Therapeutic Use
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 05 May 2023 Planned End Date changed from 1 Feb 2024 to 30 Aug 2023.
- 05 May 2023 Planned primary completion date changed from 1 Jan 2024 to 30 Aug 2023.